Table 1.
Demographics and clinical characteristics of CML cohort
| Total CML-CP Patients (n=303) | |
|---|---|
| Gender (n, %) |
|
| Male |
140 (46.2%) |
| Female |
163 (53.8%) |
| Age (mean years, SD) |
51.5 (±13.6) years |
| Time since CML diagnosis (mean years, SD) |
4.8 (±4.5) years |
| Time since CML diagnosis (n, %) |
|
| <2 years |
76 (25.1%) |
| 2 to <5 years |
90 (29.7%) |
| ≥ 5 years |
136 (44.9%) |
| Unknown |
1 (0.3%) |
| Country (n, %) |
|
| USA |
152 (50.2%) |
| Italy |
37 (12.2%) |
| Germany |
33 (10.9%) |
| Spain |
32 (10.6%) |
| United Kingdom |
25 (8.3%) |
| France |
24 (7.9%) |
| Time on Current CML Treatment (median years, IQR) |
2.75 (4.8) |
| Current CML Treatment (n, %) |
|
| Imatinib |
208 (68.6%) |
| Nilotinib |
49 (16.2%) |
| Dasatinib |
38 (12.5%) |
| Other |
4 (1.3%) |
| Decline to answer |
4 (1.3%) |
| No. of Comorbidities (mean, SD) |
1.4 (±2.4) |
| Comorbidities (n, %) |
|
| Hypertension |
49 (16.2%) |
| Insomnia/sleep difficulties |
32 (10.6%) |
| Depression |
25 (8.3%) |
| Arthritis |
24 (7.9%) |
| Anxiety |
24 (7.9%) |
| Anemia | 21 (6.9%) |
Note: CML=Chronic Myeloid Leukemia, CP=Chronic Phase, SD=Standard Deviation, IQR=Inter Quartile Range.